52-76-6
Chemical Structure
Lynestrenol
- CAS 番号: 52-76-6
- Formula:C20H28O
- Molecular Weight:284.44
IUPAC Name: (8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol
InChIKey: YNVGQYHLRCDXFQ-XGXHKTLJSA-N
SMILES: C[C@@]12[C@](CC[C@@]2(O)C#C)([H])[C@@]3([H])[C@]([C@]4([H])C(CC3)=CCCC4)([H])CC1
Biological Activity: Lynestrenol is a pregnane X receptor (PXR) agonist with the EC50s of 41 and 0.23 μM for hPXR and zfPXR, respectively[1]. Lynestrenol, a synthetic progesteronelike agent possess immunostimulatory properties[2][3].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lynestrenol | 99.92% | Lynestrenol is a pregnane X receptor (PXR) agonist with the EC50s of 41 and 0.23 μM for hPXR and zfPXR, respectively. Lynestrenol, a synthetic progesteronelike agent possess immunostimulatory properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lynestrenol (Standard) | ≥98% | Lynestrenol (Standard) is the analytical standard of Lynestrenol. This product is intended for research and analytical applications. Lynestrenol is a pregnane X receptor (PXR) agonist with the EC50s of 41 and 0.23 μM for hPXR and zfPXR, respectively. Lynestrenol, a synthetic progesteronelike agent possess immunostimulatory properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Nicolas Creusot, et al. A Comparative Study of Human and Zebrafish Pregnane X Receptor Activities of Pesticides and Steroids Using In Vitro Reporter Gene Assays. Front Endocrinol (Lausanne). 2021 May 18;12:665521. [Content Brief]
- [2]. J Wybran. Lynestrenol: a progesteronelike agent with immunostimulatory properties. Recent Results Cancer Res. 1980;75:180-4. [Content Brief]
- [3]. Yasir Hasan Siddique, et al. In vivo induction of sister chromatid exchanges (SCEs) and chromosomal aberrations (CAs) by lynestrenol. Indian J Exp Biol. 2005 Mar;43(3):291-3. [Content Brief]
Keywords